Emergent BioSolutions | EBS - أصول متداولة





أصول متداولة تغيير تاريخ
Acadia Pharmaceuticals USD 1.27B 43.88M 2026-09
Akebia Therapeutics USD 220.78M 8.77M 2026-09
ALKERMES USD 1.58B 57.83M 2026-09
Alnylam Pharmaceuticals USD 5.11B 492.49M 2026-09
Amarin USD 612.88M 10.12M 2026-09
ANI Pharmaceuticals USD 902.82M 77.39M 2026-09
BioMarin Pharmaceutical USD 3.92B 50.99M 2026-09
Coherus Biosciences USD 133.79M 72.25M 2026-06
Emergent BioSolutions USD 679.5M 41.3M 2023-12
Exelixis USD 1.32B 70.8M 2026-09
Glaxosmithkline GBP 17.9B 134M 2026-09
Heron Therapeutics USD 209.11M 20.73M 2026-09
Ionis Pharmaceuticals USD 2.36B 129.77M 2026-09
Ironwood Pharmaceuticals USD 225.99M 26.79M 2026-09
Lexicon Pharmaceuticals USD 186.03M 84.14M 2026-03
Lonza CHF 8B 3.41B 2025-12
Merck USD 38.94B 2.26B 2026-09
Moderna USD 7.34B 1.53B 2026-09
Myriad Genetics USD 289M 23.8M 2026-06
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 2.01B 370.7M 2026-09
Pacira USD 10.3B 9.68B 2026-09
Pfizer USD 45.01B 3.65B 2026-09
PTC Therapeutics USD 2.54B 79.58M 2026-09
Sanofi EUR 33.21B 1.68B 2026-09
Sarepta Therapeutics USD 2.27B 49.06M 2026-09
United Therapeutics USD 2.88B 603.5M 2026-09
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12